Price$18.02-0.02 (-0.08%)
06:30 PM07:45 PM
News · 26 weeks45+129%
2025-10-262026-04-19
Mix3290d
- Insider13(41%)
- Other10(31%)
- SEC Filings7(22%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- PRAssertio Provides Update on Garda Therapeutics Tender ProcessAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today provided an update that Garda Therapeutics, Inc. ("Garda") intends to commence the tender offer to acquire all outstanding shares of Assertio on April 29, 2026 – the day following the expiration of the 20-day "window-shop" period. As previously announced on April 8, 2026, Assertio has entered into a definitive agreement (the "Garda Agreement") to be acquired by Garda for $18.00 per share in cash, or a total cash consideration of $125.1 million, plus a contingent value right. The Garda Agreement includes a 20-day "window-shop" period. Under the terms of the window-shop provision, Assertio is free to engage with othe
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC TO-C filed by Assertio Holdings Inc.SC TO-C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAmendment: Assertio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K/A - Assertio Holdings, Inc. (0001808665) (Filer)
- ANALYSTAssertio Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Assertio Therapeutics from Buy to Neutral and set a new price target of $18.00
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC TO-C filed by Assertio Holdings Inc.SC TO-C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- PRCosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio-- Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence -- -- SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette -- -- Additional Brands include INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (NASDAQ:ASRT). The acquisition expands Cosette's branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advanc
- PRAssertio Announces Agreement to be Acquired by Garda TherapeuticsAll-Cash Tender Offer of $18 per share – or $125.1 Million – Plus Contingent Value Right Tender Offer Price Represents 34.6% Premium to Unaffected Price and 46.6% Premium to Unaffected 30-day Volume-Weighted Average Price Transaction Follows Comprehensive Strategic Review Process Initiated in First Quarter of 2025 Includes Additional "Shop" Period to Ensure Maximum Value for Shareholders Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced a definitive agreement (the "Garda Agreement") to be acquired by Garda Therapeutics ("Garda" or the "Buyer") for $18 per share in cash, or a total cash consideration of $125.1 million, (the "Garda Transaction"), plu
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Assertio Holdings Inc.SCHEDULE 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form DEF 14A filed by Assertio Holdings Inc.DEF 14A - Assertio Holdings, Inc. (0001808665) (Filer)
- SECSEC Form 10-K filed by Assertio Holdings Inc.10-K - Assertio Holdings, Inc. (0001808665) (Filer)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- INSIDERSEC Form 4 filed by EVP, General Counsel Schlessinger Sam4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Patel Ajay4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERSEC Form 4 filed by President and COO Schwichtenberg Paul4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERSEC Form 4 filed by CEO Reisenauer Mark L4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- PRAssertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026Assertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wis
- INSIDEREVP, General Counsel Schlessinger Sam converted options into 1,143 shares and covered exercise/tax liability with 510 shares, increasing direct ownership by 4% to 14,738 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDEREVP and CFO Patel Ajay converted options into 1,143 shares and covered exercise/tax liability with 566 shares, increasing direct ownership by 4% to 15,942 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)